GlassScriptPhysician profile
Jeffrey Allen Strakowski
NPI 1245389733
$59,100.48
in general payments reported to CMS, 2019-2025
25 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,086 · 2020: $337 · 2021: $845 · 2022: $2,868 · 2023: $18K · 2024: $7,368 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $41K · Travel and Lodging: $5,567 · Food and Beverage: $2,234 · Education: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $41,377.96 |
| Travel and Lodging | $5,567.36 |
| Food and Beverage | $2,233.77 |
| Education | $785.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cadwell Industries, INC | $45,266.96 | 2019-2025 | |
| Natus Medical Incorporated | $9,877.96 | 2022-2025 | |
| Abbvie INC. | $917.33 | 2022-2025 | Botox |
| Allergan, INC. | $703.61 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $686.50 | 2019-2023 | Relistor |
| Canon Medical Systems USA, INC. | $339.31 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $196.37 | 2019-2023 | Xtampza |
| Biohaven Pharmaceutical Holding Company LTD. | $144.77 | 2022 | |
| Medtronic, INC. | $129.68 | 2025 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $109.52 | 2019-2020 | |
| Integra Lifesciences Corporation | $102.94 | 2021 | |
| Biodelivery Sciences International, INC. | $99.12 | 2019-2021 | |
| Amgen INC. | $75.08 | 2019-2022 | |
| Pfizer INC. | $64.44 | 2019-2023 | |
| Boston Scientific Corporation | $60.38 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.23 | 2019-2021 | |
| Zyla Life Sciences, INC. | $55.48 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $44.65 | 2020-2024 | Dysport |
| Abbott Laboratories | $40.75 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.22 | 2021 | |
| Vertical Pharmaceuticals, LLC | $25.12 | 2019 | |
| Nevro Corp. | $21.48 | 2019 | |
| Merz Pharmaceuticals, LLC | $20.98 | 2025 | Xeomin |
| Fujifilm Sonosite, INC. | $17.65 | 2024 | |
| Shionogi INC | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Strakowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.